Moreover, the 36-month beta value for VXRT is 0.63. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VXRT is 225.47M and currently, short sellers hold a 5.01% of that float. On December 26, 2024, VXRT’s average trading volume was 1.32M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VXRT) stock’s latest price update
Vaxart Inc (NASDAQ: VXRT)’s stock price has soared by 1.84 in relation to previous closing price of 0.61. Nevertheless, the company has seen a gain of 14.81% in its stock price over the last five trading days. globenewswire.com reported 2024-12-02 that SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart’s COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator.
VXRT’s Market Performance
VXRT’s stock has risen by 14.81% in the past week, with a monthly rise of 1.29% and a quarterly drop of -23.27%. The volatility ratio for the week is 10.38% while the volatility levels for the last 30 days are 7.75% for Vaxart Inc. The simple moving average for the past 20 days is 3.03% for VXRT’s stock, with a -21.52% simple moving average for the past 200 days.
Analysts’ Opinion of VXRT
Many brokerage firms have already submitted their reports for VXRT stocks, with Oppenheimer repeating the rating for VXRT by listing it as a “Outperform.” The predicted price for VXRT in the upcoming period, according to Oppenheimer is $4 based on the research report published on August 15, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $12, previously predicting the price at $13. The rating they have provided for VXRT stocks is “Buy” according to the report published on December 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to VXRT, setting the target price at $15 in the report published on November 02nd of the previous year.
VXRT Trading at -7.58% from the 50-Day Moving Average
After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.74% of loss for the given period.
Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 10.38%, as shares surge +4.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.98% lower at present.
During the last 5 trading sessions, VXRT rose by +16.48%, which changed the moving average for the period of 200-days by -44.82% in comparison to the 20-day moving average, which settled at $0.6022. In addition, Vaxart Inc saw 8.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VXRT starting from Watson W. Mark, who purchase 20,000 shares at the price of $0.68 back on Jun 18 ’24. After this action, Watson W. Mark now owns 78,125 shares of Vaxart Inc, valued at $13,578 using the latest closing price.
Stock Fundamentals for VXRT
Current profitability levels for the company are sitting at:
- -4.28 for the present operating margin
- -0.18 for the gross margin
The net margin for Vaxart Inc stands at -4.32. The total capital return value is set at -0.83. Equity return is now at value -103.37, with -53.13 for asset returns.
Currently, EBITDA for the company is -74.72 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 8.25. The receivables turnover for the company is 4.56for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.83.
Conclusion
To wrap up, the performance of Vaxart Inc (VXRT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
